Evidence map›Paper›PMID 24524071›Full record

ReviewBioMed research international2014

Heat shock protein 72 expressing stress in sepsis: unbridgeable gap between animal and human studies--a hypothetical "comparative" study.

George Briassoulis, Efrossini Briassouli, Diana-Michaela Fitrolaki, Ioanna Plati, Kleovoulos Apostolou, Theonymfi Tavladaki, Anna-Maria Spanaki

Open access · hybridAbstract readComparative StudyReview
In one paragraph

Review in BioMed research international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. HSP-Target of Therapeutic Agents in Sepsis Treatment.International journal of molecular sciences · 2019
    Review
  6. Article
  7. Article
  8. Observational
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

George BriassoulisPediatric Intensive Care Unit, University Hospital, School of Health Sciences, University of Crete, Voutes Area, 71110 Heraklion, Crete, Greece.ORCID 0000-0003-0928-6183
Efrossini Briassouli1st Department of Propaedeutic Internal Medicine, Laiko, University General Hospital, University of Athens, 17 Agiou Thoma, 115 27 Athens, Greece.
Diana-Michaela FitrolakiPediatric Intensive Care Unit, University Hospital, School of Health Sciences, University of Crete, Voutes Area, 71110 Heraklion, Crete, Greece.
Ioanna PlatiDepartment of Clinical Chemistry, School of Medicine, University of Crete, Voutes Area, 71110 Heraklion, Crete, Greece.
Kleovoulos ApostolouNational and Kapodistrian University of Athens, First Critical Care Department, Evaggelismos Hospital, Ipsilantou 45, 10676, Athens, Greece.
Theonymfi TavladakiPediatric Intensive Care Unit, University Hospital, School of Health Sciences, University of Crete, Voutes Area, 71110 Heraklion, Crete, Greece.
Anna-Maria SpanakiPediatric Intensive Care Unit, University Hospital, School of Health Sciences, University of Crete, Voutes Area, 71110 Heraklion, Crete, Greece.
University of Crete · GRNational and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heat shock protein 72 (Hsp72) exhibits a protective role during times of increased risk of pathogenic challenge and/or tissue damage. The aim of the study was to ascertain Hsp72 protective effect differences between animal and human studies in sepsis using a hypothetical "comparative study" model. Forty-one in vivo (56.1%), in vitro (17.1%), or combined (26.8%) animal and 14 in vivo (2) or in vitro (12) human Hsp72 studies (P < 0.0001) were enrolled in the analysis. Of the 14 human studies, 50% showed a protective Hsp72 effect compared to 95.8% protection shown in septic animal studies (P < 0.0001). Only human studies reported Hsp72-associated mortality (21.4%) or infection (7.1%) or reported results (14.3%) to be nonprotective (P < 0.001). In animal models, any Hsp72 induction method tried increased intracellular Hsp72 (100%), compared to 57.1% of human studies (P < 0.02), reduced proinflammatory cytokines (28/29), and enhanced survival (18/18). Animal studies show a clear Hsp72 protective effect in sepsis. Human studies are inconclusive, showing either protection or a possible relation to mortality and infections. This might be due to the fact that using evermore purified target cell populations in animal models, a lot of clinical information regarding the net response that occurs in sepsis is missing.

Indexed as

AnimalsDisease Models, AnimalHSP72 Heat-Shock ProteinsHumansSepsisTumor Necrosis Factor-alphaHSP72 Heat-Shock ProteinsTumor Necrosis Factor-alpha

Identifiers

PMID24524071
PMCPMC3912989
OpenAlexW1983069831

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.